ScoreWhy is Xeris Biopharma Holdings, Inc. ?
1
With a growth in Net Profit of 1684.38%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 10.56 MM
- NET SALES(Q) Highest at USD 74.38 MM
- RAW MATERIAL COST(Y) Fallen by -16.84% (YoY)
2
With ROE of 1564.10%, it has a fair valuation with a -946.65 Price to Book Value
- Over the past year, while the stock has generated a return of -3.44%, its profits have risen by 76.6%
3
High Institutional Holdings at 71.22%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 5.61% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Xeris Biopharma Holdings, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xeris Biopharma Holdings, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xeris Biopharma Holdings, Inc.
-3.44%
2.30
61.77%
S&P 500
16.12%
0.84
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
77.44%
EBIT Growth (5y)
16.02%
EBIT to Interest (avg)
-5.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.05
Sales to Capital Employed (avg)
0.93
Tax Ratio
5.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
71.22%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-946.65
EV to EBIT
110.25
EV to EBITDA
48.18
EV to Capital Employed
8.11
EV to Sales
4.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.36%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend31What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 10.56 MM
NET SALES(Q)
Highest at USD 74.38 MM
RAW MATERIAL COST(Y)
Fallen by -16.84% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -19,286.41 %
DEBTORS TURNOVER RATIO(HY)
Highest at 5.61 times
OPERATING PROFIT(Q)
Highest at USD 9.92 MM
OPERATING PROFIT MARGIN(Q)
Highest at 13.34 %
PRE-TAX PROFIT(Q)
Highest at USD 0.62 MM
NET PROFIT(Q)
Highest at USD 0.62 MM
EPS(Q)
Highest at USD 0
-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.92 times
Here's what is working for Xeris Biopharma Holdings, Inc.
Operating Cash Flow
Highest at USD 10.56 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 74.38 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 0.62 MM has Grown at 106.95%
over average net sales of the previous four periods of USD -8.94 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 0.62 MM has Grown at 107.66%
over average net sales of the previous four periods of USD -8.1 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 74.38 MM has Grown at 20.93%
over average net sales of the previous four periods of USD 61.51 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 9.92 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 13.34 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 0.62 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 0.62 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -19,286.41 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 5.61 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -16.84% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 3.19 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Xeris Biopharma Holdings, Inc.
Inventory Turnover Ratio
Lowest at 0.92 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
